F Cognetti1, E M Ruggeri2, A Felici3, M Gallucci4, G Muto5, C F Pollera2, B Massidda6, A Rubagotti7, D Giannarelli8, F Boccardo9. 1. Department of Medical Oncology, Regina Elena Cancer Institute, Rome. Electronic address: cognetti@ifo.it. 2. Division of Medical Oncology, Belcolle Hospital, Viterbo. 3. Department of Medical Oncology, Regina Elena Cancer Institute, Rome. 4. Department of Urology, Regina Elena Cancer Institute, Rome. 5. Department of Urology, San Giovanni Bosco Hospital, Torino. 6. Department of Medical Oncology, Policlinico Universitario, Cagliari. 7. Departments of Medical Oncology and of Oncology, Biology and Genetics (Biostatistics Unit), National Cancer Research Institute and University, Genova; Departments of Medical Oncology and of Oncology, Biology and Genetics, National Cancer Research Institute and University, Genova. 8. Department of Biostatistics, Regina Elena Cancer Institute, Rome, Italy. 9. Departments of Medical Oncology and of Oncology, Biology and Genetics, National Cancer Research Institute and University, Genova.
Abstract
BACKGROUND: The purpose of the study was to evaluate the benefit of adjuvant chemotherapy (AC) versus surgery alone in patients with muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: One hundred and ninety-four patients with pT2G3, pT3-4, N0-2 transitional cell bladder carcinoma were randomly allocated to control (92 patients) or to four courses of AC (102 patients). These latter patients were further randomly assigned to receive gemcitabine 1000 mg/m(2) days 1, 8 and 15 and cisplatin 70 mg/m(2) day 2 or gemcitabine as above plus cisplatin 70 mg/m(2) day 15, every 28 days. RESULTS: At a median follow-up of 35 months, the 5-year overall survival (OS) was 48.5%, with no difference between the two arms [P = 0.24, hazard ratio (HR) 1.29, 95% confidence interval (CI) 0.84-1.99]. Mortality hazard was significantly correlated with Nodes (N) and Tumor (T) stage. The control and AC arms had comparable disease-free survival (42.3% and 37.2%, respectively; P = 0.70, HR 1.08, 95% CI 0.73-1.59). Only 62% of patients received the planned cycles. A significant higher incidence of thrombocytopenia was observed in patients receiving cisplatin on day 2 (P = 0.006). A similar global quality of life was observed in the two arms. CONCLUSION: The study was underpowered to demonstrate that AC with cisplatin and gemcitabine improves OS and disease-free survival in patients with MIBC.
RCT Entities:
BACKGROUND: The purpose of the study was to evaluate the benefit of adjuvant chemotherapy (AC) versus surgery alone in patients with muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: One hundred and ninety-four patients with pT2G3, pT3-4, N0-2 transitional cell bladder carcinoma were randomly allocated to control (92 patients) or to four courses of AC (102 patients). These latter patients were further randomly assigned to receive gemcitabine 1000 mg/m(2) days 1, 8 and 15 and cisplatin 70 mg/m(2) day 2 or gemcitabine as above plus cisplatin 70 mg/m(2) day 15, every 28 days. RESULTS: At a median follow-up of 35 months, the 5-year overall survival (OS) was 48.5%, with no difference between the two arms [P = 0.24, hazard ratio (HR) 1.29, 95% confidence interval (CI) 0.84-1.99]. Mortality hazard was significantly correlated with Nodes (N) and Tumor (T) stage. The control and AC arms had comparable disease-free survival (42.3% and 37.2%, respectively; P = 0.70, HR 1.08, 95% CI 0.73-1.59). Only 62% of patients received the planned cycles. A significant higher incidence of thrombocytopenia was observed in patients receiving cisplatin on day 2 (P = 0.006). A similar global quality of life was observed in the two arms. CONCLUSION: The study was underpowered to demonstrate that AC with cisplatin and gemcitabine improves OS and disease-free survival in patients with MIBC.
Authors: Felix V Chen; Tulay Koru-Sengul; Feng Miao; Joshua S Jue; Mahmoud Alameddine; Devina J Dave; Sanoj Punnen; Dipen J Parekh; Chad R Ritch; Mark L Gonzalgo Journal: Urol Oncol Date: 2019-08-14 Impact factor: 3.498
Authors: Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo Journal: Clin Genitourin Cancer Date: 2015-03-05 Impact factor: 2.872